Literature DB >> 22896029

Increased organ damage associated with deterioration in volumetric bone density and bone microarchitecture in patients with systemic lupus erythematosus on longterm glucocorticoid therapy.

Xiao Lin Tang1, Tracy Yaner Zhu, Vivian W Hung, Ling Qin, Chun-Kwok Wong, Emily W Kun, Lai Shan Tam, Edmund K Li.   

Abstract

OBJECTIVE: To evaluate bone quality in patients with systemic lupus erythematosus (SLE) who were undergoing longterm glucocorticoid (GC) therapy, and to focus on the correlation between bone quality and organ damage.
METHODS: Seventy-eight female patients with SLE and organ damage taking longterm GC, and 72 age-matched SLE patients without damage taking longterm GC were recruited for study. Clinical variables of interest included disease activity, cumulative organ damage (by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SDI), major organ involvement (musculoskeletal damage and neuropsychiatric damage, etc.), and use of medication. Areal bone mineral density (aBMD) was measured by dual-energy X-ray absorptiometry. Bone geometry, volumetric BMD (vBMD), microarchitecture, and biomechanical properties were measured by high-resolution peripheral quantitative computed tomography (HR-pQCT).
RESULTS: Patients were mean age of 45 years (SD 10) and 54% were postmenopausal. The median SDI score of the cohort was 1 (interquartile range 1-2, range 1-5). Compared with patients without damage, the prevalence of osteopenia at either total hip or lumbar spine was significantly higher, and there were trends of deterioration of bone geometry, vBMD, microarchitecture, and biomechanical properties in patients with organ damage. Potential risk factors for bone quality in patients with damage were screened by univariate analysis. During multiple regression analysis, SDI was the only clinical variable consistently associated with deterioration of vBMD and microarchitecture.
CONCLUSION: Cumulative organ damage consistently correlated with deterioration of vBMD and bone microarchitecture in SLE patients with damage on longterm GC therapy. HR-pQCT provides an insight into the underlying mechanism of bone loss in SLE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896029     DOI: 10.3899/jrheum.120213

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus.

Authors:  J A Paupitz; G L Lima; J C Alvarenga; R M Oliveira; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

2.  Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study.

Authors:  T Y Zhu; J F Griffith; L Qin; V W Y Hung; T-N Fong; S-K Au; X-L Tang; E W Kun; A W Kwok; P-C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2015-03-04       Impact factor: 4.507

3.  Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT.

Authors:  X L Tang; L Qin; A W Kwok; T Y Zhu; E W Kun; V W Hung; J F Griffith; P C Leung; E K Li; L-S Tam
Journal:  Osteoporos Int       Date:  2012-10-27       Impact factor: 4.507

4.  Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis.

Authors:  Jumei Xia; Ran Luo; Shuiming Guo; Yi Yang; Shuwang Ge; Gang Xu; Rui Zeng
Journal:  Biomed Res Int       Date:  2019-02-20       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.